Literature DB >> 20428268

Reactive oxygen species in early and delayed cardiac adaptation.

E Roth1, M T Jaberansari.   

Abstract

This review focuses on the role of reactive oxygen species in the pathogenesis of cardiac adaptation to ischemia. Results from various laboratories including the authors' confirm the assumption that reactive oxygen species can be an integral part of the induction of both early and delayed forms of cardioprotection. There is conclusive evidence that reactive oxygen species may lead to activation of protein kinase C, protein tyrosine kinase, ionic channel openings and activation of transcriptional factors, all of which may translate into cardioprotection. These findings unveil a contradictory yet fascinating concept that oxygen radicals, although well recognized for their toxicity, can, under special circumstances, beneficially alter cell function leading to increased cell tolerance and survival.

Entities:  

Keywords:  Ischemic preconditioning; Myocardial protection; Reactive oxygen species

Year:  2001        PMID: 20428268      PMCID: PMC2859010     

Source DB:  PubMed          Journal:  Exp Clin Cardiol        ISSN: 1205-6626


  51 in total

1.  Direct evidence that initial oxidative stress triggered by preconditioning contributes to second window of protection by endogenous antioxidant enzyme in myocytes.

Authors:  X Zhou; X Zhai; M Ashraf
Journal:  Circulation       Date:  1996-03-15       Impact factor: 29.690

2.  Direct evidence that protein kinase C plays an essential role in the development of late preconditioning against myocardial stunning in conscious rabbits and that epsilon is the isoform involved.

Authors:  Y Qiu; P Ping; X L Tang; S Manchikalapudi; A Rizvi; J Zhang; H Takano; W J Wu; S Teschner; R Bolli
Journal:  J Clin Invest       Date:  1998-05-15       Impact factor: 14.808

3.  Opening of mitochondrial K(ATP) channels triggers the preconditioned state by generating free radicals.

Authors:  T Pain; X M Yang; S D Critz; Y Yue; A Nakano; G S Liu; G Heusch; M V Cohen; J M Downey
Journal:  Circ Res       Date:  2000-09-15       Impact factor: 17.367

4.  Ischemic preconditioning induces selective translocation of protein kinase C isoforms epsilon and eta in the heart of conscious rabbits without subcellular redistribution of total protein kinase C activity.

Authors:  P Ping; J Zhang; Y Qiu; X L Tang; S Manchikalapudi; X Cao; R Bolli
Journal:  Circ Res       Date:  1997-09       Impact factor: 17.367

5.  Limitation of infarct size in the rabbit by ischaemic preconditioning is reversible with glibenclamide.

Authors:  C F Toombs; T L Moore; R J Shebuski
Journal:  Cardiovasc Res       Date:  1993-04       Impact factor: 10.787

6.  Identification of MAPKAP kinase 2 as a major enzyme responsible for the phosphorylation of the small mammalian heat shock proteins.

Authors:  D Stokoe; K Engel; D G Campbell; P Cohen; M Gaestel
Journal:  FEBS Lett       Date:  1992-11-30       Impact factor: 4.124

7.  Adenosine receptor involvement in a delayed phase of myocardial protection 24 hours after ischemic preconditioning.

Authors:  G F Baxter; M S Marber; V C Patel; D M Yellon
Journal:  Circulation       Date:  1994-12       Impact factor: 29.690

8.  Ischaemic preconditioning is not mediated by oxygen derived free radicals in rats.

Authors:  V Richard; C Tron; C Thuillez
Journal:  Cardiovasc Res       Date:  1993-11       Impact factor: 10.787

9.  Blockade of ATP-sensitive potassium channels prevents myocardial preconditioning in dogs.

Authors:  G J Gross; J A Auchampach
Journal:  Circ Res       Date:  1992-02       Impact factor: 17.367

10.  An essential role of NFkappaB in tyrosine kinase signaling of p38 MAP kinase regulation of myocardial adaptation to ischemia.

Authors:  N Maulik; M Sato; B D Price; D K Das
Journal:  FEBS Lett       Date:  1998-06-16       Impact factor: 4.124

View more
  1 in total

1.  The role of free radicals in endogenous adaptation and intracellular signals.

Authors:  E Röth; L Hejjel; Mt Jaberansari; G Jancso
Journal:  Exp Clin Cardiol       Date:  2004
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.